Events

Rappel de ACTIVA RC NEUROSTIMULATOR - DBS EXTENSION KIT FOR DEEP BRAIN STIMULATION

Selon Health Canada (via FOI), ce/cet/cette rappel concerne un dispositif en/au/aux/à Canada qui a été fabriqué par MEDTRONIC OF CANADA LTD..

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    111327
  • Classe de risque de l'événement
    II
  • Date de mise en oeuvre de l'événement
    2016-05-17
  • Pays de l'événement
    Canada
  • Source de l'événement
    HC
  • Notes / Alertes
    Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
  • Notes supplémentaires dans les données
  • Cause
    Notification regarding information that will be added in the future to medtronic's deep brain stimulation (dbs) labeling. the labeling updates further clarify potential risks which have been reported with dbs therapy. medtronic is sharing this information to help with management of current and future patients treated with dbs therapy. medical safety assessment evaluated reports of a loss of swimming ability or drowning following dbs implant. the dbs manuals reviewed as part of the msa identified language describing the potential for loss of coordination however this language does not describe the potential for changes in swimming ability due to dbs therapy and the associated risk of drowning in the dbs patient population. medical safety assessment (msa) evaluated reports of serious injury associated with tunneling for dbs therapy. the dbs manuals reviewed as part of the msa do not describe some of the risks associated with tunneling identified in the msa which include spinal accessory nerve injury vascular injury tunneling too deeply too superficially or tunneling through unintended anatomy (such as in between the ribs or entering the thoracic cavity). note: the tunneling tool model associated with these injuries was not reported for some of these events.

Device

ACTIVA RC NEUROSTIMULATOR - DBS EXTENSION KIT FOR DEEP BRAIN STIMULATION
  • Modèle / numéro de série
    Model Catalog: 37086 (Lot serial: All Lots); Model Catalog: 7428 (Lot serial: All Lots); Model Catalog: 37603 (Lot serial: All Lots); Model Catalog: 37602 (Lot serial: All Lots); Model Catalog: 37612 (Lot serial: All Lots); Model Catalog: 37601 (Lot serial: All Lots); Model Catalog: 7426 (Lot serial: All Lots); Model Catalog: 7483 (Lot serial: All Lots)
  • Description du dispositif
    ACTIVA RC NEUROSTIMULATOR - DBS EXTENSION KIT FOR DEEP BRAIN STIMULATION;KINETRA NEUROSTIMULATOR PULSE GENERATOR & ACCESSORY KIT;ACTIVA SC - NEUROSTIMULATOR;ACTIVA PC INS - DBS EXTENSION KIT FOR DEEP BRAIN STIMULATION;ACTIVA RC MULTI-PROGRAM RECHARGEABLE
  • Manufacturer
    MEDTRONIC OF CANADA LTD.

Manufacturer

MEDTRONIC OF CANADA LTD.
  • Adresse du fabricant
    BRAMPTON
  • Société-mère du fabricant (2017)
    Medtronic plc
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    HC